This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts' Actions: CFR DDD LH NVDA UAL

NEW YORK (TheStreet) -- RATINGS CHANGES

BioTelemetry (BEAT) was upgraded to hold at TheStreet Ratings.

General Cable (BGC) was downgraded at DA Davidson to neutral from buy. Twelve-month price target is $28. Estimates were also cut, given the company's new guidance, DA Davidson said.

Cullen/Frost (CFR) was upgraded at Sterne Agee to neutral from underperform. Valuation call, based on a 12-month price target of $74, Sterne Agee said.

3D Systems (DDD) was initiated at UBS with a neutral rating. Company has broad product line and acquisition strategy, but bumpy near-term financials, UBS said. Twelve-month price target is $62.

Genie Energy (GNE) was initiated with a hold rating at TheStreet Ratings.

Invensense (INVN) was downgraded at Oppenheimer to perform from outperform. Company could face increased competition, Oppenheimer said.

Laboratory Corporation of America (LH) was upgraded at UBS to neutral from buy. Driven by lab industry's successful efforts to push off Medicare CLFS changes until 2017, UBS said. Twelve-month price target is $112.

Mednax (MD) was upgraded at Deutsche Bank to buy from hold. Twelve-month price target is $73. Company can deliver higher organic growth, Deutsche Bank said.

Nvidia (NVDA - Get Report) was upgraded at JMP Securities to outperform from market perform. Twelve-month price target is $26. Company is focused on increasing gross margin, JMP said.

Stratasys (SSYS) was initiated at UBS with a buy rating. Better execution and narrower focus compared to comparables, UBS said. Twelve-month price target is $125.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
NVDA $22.20 0.27%
UAL $54.58 2.00%
AAPL $130.96 -0.62%
FB $79.32 -1.00%
GOOG $534.72 -0.94%

Markets

DOW 18,054.42 -71.70 -0.40%
S&P 500 2,114.84 -5.95 -0.28%
NASDAQ 5,092.0420 -5.9340 -0.12%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs